1. New Biogen data showed no major safety issues for its Alzheimer's drug — Lilly puts its oncology future in Lox’s hands — Sage Therapeutics depression drug fails phase 3 trial — See more on our front page news

    TRY TWO WEEKS OF OUR EMAIL NEWS HEADLINES FOR FREE
    Dismiss Notice
  2. Think you have witnessed fraud?Ask a Whistleblower Attorney -- a chance to discuss whistleblower-related legal issues with practicing whistleblower attorneys.
    Dismiss Notice

Anti-Infective Position

Discussion in 'Allergan' started by anonymous, Apr 5, 2018 at 11:04 AM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    This should ease your anxiety. I pasted the most interesting paragraph below...

    https://www.fool.com/investing/2019/06/26/heres-why-nobodys-happy-about-this-63-billion-buyo.aspx


    Since these companies have a lot of overlapping departments, a lot of Allergan employees will probably receive a severance package and a box for their personal items before the end of the year. Altogether, AbbVie expects to trim more than $2 billion annually from Allergan's operations. That shouldn't be too difficult -- over the past year, operating expenses for the pair reached $18.7 billion and $13.0 billion, respectively.
     

  2. anonymous

    anonymous Guest

    Not sure how this eases our anxiety
     
  3. anonymous

    anonymous Guest

    It was meant to be sarcastic!